Indication
In adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin; or,
- alone or in combination wtih other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statis is contraindicated.
Medicine details
- Medicine name:
- bempedoic acid (Nilemdo)
- SMC ID:
- SMC2292
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- Submission type
- Full
- Publication due date:
- 07 December 2020
- SMC meeting date:
- 03 November 2020
- Patient group submission deadline:
- 05 October 2020